ArticleIJID regions2025
Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From 10-Valent to 21-Valent Pneumococcal Conjugate Vaccines: Divergent Global Pathways and Future Directions for India.Indian pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Four pneumococcal conjugate vaccines (PCVs) are available for infant immunization in India's private sector: a 13-valent (PCV13-PFE), two 10-valent (PCV10-GSK, PCV10-SII), and a 14-valent (PCV14-BE). Methods: Based on the India label dosing for each, a decision-analytic Markov model was used to compare the health and economic impacts and cost-effectiveness of PCV13-PFE (3+1) vs PCV10-SII (3+0), PCV10-GSK (3+1), or PCV14-BE (3+0). Pneumococcal disease (PD) incidence, serotype distribution, costs, and utility inputs were derived from published studies and local evidence. Adjustment for the estimated direct vaccine effects following the specified dosing schedules was applied to PCV10-SII and PCV14-BE. A willingness-to-pay threshold of INR 590,949 per quality-adjusted life-year (QALY) was used to assess cost-effectiveness. Results: PCV13-PFE was estimated to prevent an additional 255,060, 40,336, and 247,750 total cases of PD compared to PCV10-SII, PCV10-GSK, and PCV14-BE, respectively, over 10 years. Compared to these alternative PCVs, PCV13-PFE was estimated to result in additional direct disease cost savings of INR 22.5 billion, INR 3.63 billion, and INR 21.9 billion from PD cases prevented. This yielded incremental cost-effectiveness ratios (ICERs) for PCV13-PFE vs PCV10-SII and PCV10-GSK of INR 18,142 and INR 304,234 per QALY, respectively, both below the willingness-to-pay threshold of INR 590,949. PCV13-PFE was cost-saving compared to PCV14-BE. Conclusions: From the private sector perspective, vaccinating children in India with PCV13-PFE could prevent more PD cases, save more PD-associated medical costs, and be more cost-effective than other locally available PCV options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.